Markers of clinical utility in the differential diagnosis and prognosis of prostate cancer (Q47215343)

11 January 2018

review article

1 reference

title

Markers of clinical utility in the differential diagnosis and prognosis of prostate cancer (English)

1 reference

11 January 2018

author name string

Glen Kristiansen

series ordinal

1 reference

11 January 2018

publication date

1 January 2018

1 reference

11 January 2018

published in

Modern Pathology

1 reference

11 January 2018

volume

1 reference

11 January 2018

issue

1 reference

11 January 2018

page(s)

S143-155

1 reference

11 January 2018

cites work

Cancer Statistics, 2017.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Oldest known case of metastasizing prostate carcinoma diagnosed in the skeleton of a 2,700-year-old Scythian king from Arzhan (Siberia, Russia).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Mortality results from a randomized prostate-cancer screening trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Follow-up of Prostatectomy versus Observation for Early Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

The Current State of MR Imaging-targeted Biopsy Techniques for Detection of Prostate Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

p63 is a prostate basal cell marker and is required for prostate development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Comparison of p40 (ΔNp63) and p63 expression in prostate tissues--which one is the superior diagnostic marker for basal cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

ΔNp63 (p40) expression in prostatic adenocarcinoma with diffuse p63 positivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Aberrant diffuse expression of p63 in adenocarcinoma of the prostate on needle biopsy and radical prostatectomy: report of 21 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

P504S: a new molecular marker for the detection of prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Alpha-methylacyl-CoA racemase: a variably sensitive immunohistochemical marker for the diagnosis of small prostate cancer foci on needle biopsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Small glandular proliferations on needle biopsies: most common benign mimickers of prostatic adenocarcinoma sent in for expert second opinion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Expression of α-methylacyl-coa racemase (p504s) in various malignant neoplasms and normal tissues: a study of 761 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

GOLPH2 and MYO6: putative prostate cancer markers localized to the Golgi apparatus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

GOLPH2 expression in renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

GOLPH2 expression may serve as diagnostic marker in seminomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

The diagnostic utility of novel immunohistochemical marker ERG in the workup of prostate biopsies with "atypical glands suspicious for cancer".

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Prostein expression is highly restricted to normal and malignant prostate tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

A Novel Human Prostate-Specific, Androgen-Regulated Homeobox Gene (NKX3.1) That Maps to 8p21, a Region Frequently Deleted in Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Comparison of different prostatic markers in lymph node and distant metastases of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

HOXB13 as an immunohistochemical marker of prostatic origin in metastatic tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

HOXB13 protein expression in metastatic lesions is a promising marker for prostate origin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Expression analysis onto microarrays of randomly selected cDNA clones highlights HOXB13 as a marker of human prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Comprehensive validation of published immunohistochemical prognostic biomarkers of prostate cancer -what has gone wrong? A blueprint for the way forward in biomarker studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

The Ki-67 protein: from the known and the unknown

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Diagnostic and prognostic molecular biomarkers for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Did the reporting of prognostic studies of tumour markers improve since the introduction of REMARK guideline? A comparison of reporting in published articles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Reporting recommendations for tumor marker prognostic studies (REMARK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

An international Ki67 reproducibility study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

The region-of-interest size impacts on Ki67 quantification by computer-assisted image analysis in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Strategies for developing Ki67 as a useful biomarker in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Prognostic relevance of proliferation markers (Ki-67, PHH3) within the cross-relation of ERG translocation and androgen receptor expression in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

PTEN loss and chromosome 8 alterations in Gleason grade 3 prostate cancer cores predicts the presence of un-sampled grade 4 tumor: implications for active surveillance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Tumour heterogeneity poses a significant challenge to cancer biomarker research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

ERG protein expression in diagnostic specimens is associated with increased risk of progression during active surveillance for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Epigenetics in Prostate Cancer: Biologic and Clinical Relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Performance evaluation of kits for bisulfite-conversion of DNA from tissues, cell lines, FFPE tissues, aspirates, lavages, effusions, plasma, serum, and urine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Hypermethylation of genes for diagnosis and risk stratification of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

DNA methylation of the PITX2 gene promoter region is a strong independent prognostic marker of biochemical recurrence in patients with prostate cancer after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

PITX2 DNA Methylation as Biomarker for Individualized Risk Assessment of Prostate Cancer in Core Biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Repeat Prostate Biopsy: Rationale, Indications, and Strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Prostate cancer: state of the art imaging and focal treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Histopathological screening for prostate carcinoma: is a benign biopsy a negative biopsy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Clinical validation of an epigenetic assay to predict negative histopathological results in repeat prostate biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Delineation of prognostic biomarkers in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Expression profiling of microdissected matched prostate cancer samples reveals CD166/MEMD and CD24 as new prognostic markers for patient survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

An expression signature at diagnosis to estimate prostate cancer patients' overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Gene expression profiling identifies clinically relevant subtypes of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Molecular sampling of prostate cancer: a dilemma for predicting disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Gene expression studies in prostate cancer tissue: which reference gene should be selected for normalization?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

[Molecular biomarkers and prognostic factors for prostate cancer].

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Prognostic Value of the Cell Cycle Progression Score in Patients with Prostate Cancer: A Systematic Review and Meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Cell-cycle Progression-score Might Improve the Current Risk Assessment in Newly Diagnosed Prostate Cancer Patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Clinically available RNA profiling tests of prostate tumors: utility and comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Decipher Genomic Classifier Measured on Prostate Biopsy Predicts Metastasis Risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Decipher correlation patterns post prostatectomy: initial experience from 2 342 prospective patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Molecular Analysis of Low Grade Prostate Cancer Using a Genomic Classifier of Metastatic Potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

HOXB13 is a sensitive and specific marker of prostate cells, useful in distinguishing between carcinomas of prostatic and urothelial origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

DNA methylation ofPITX2predicts poor survival in men with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

Multiparametric MRI fusion-guided biopsy for the diagnosis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

7 January 2021

Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

7 January 2021

[Immunohistochemical algorithms in prostate diagnostics: what's new?]

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

7 January 2021

Analysis of alpha-methylacyl-CoA racemase (P504S) expression in high-grade prostatic intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

7 January 2021

Expression of alpha-methylacyl-CoA racemase in papillary renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

7 January 2021

Expression of alpha-methylacyl-CoA racemase correlates with histopathologic grading in noninvasive bladder cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

7 January 2021

Comparison of the diagnostic value of fatty acid synthase (FASN) with alpha-methylacyl-CoA racemase (AMACR) as prostatic cancer tissue marker

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

7 January 2021

Left laparoscopic radical nephrectomy in the presence of a duplicated inferior vena cava with complicated anomalous tributaries by a transmesocolic approach

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

7 January 2021

Glutathione S-transferase-pi protein expression in prostate cancer-not always a useful diagnostic tool

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

7 January 2021

Immunohistochemical Identification of Prostatic Acid Phosphatase: Correlation of Tumor Grade with Acid Phosphatase Distribution

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

7 January 2021

Value of a panel of antibodies to identify the primary origin of adenocarcinomas presenting as bladder carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

7 January 2021

PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

7 January 2021

Marked heterogeneity of ERG expression in large primary prostate cancers

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

7 January 2021

A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

7 January 2021

Prediction efficiency of PITX2 DNA methylation for prostate cancer survival.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

7 January 2021

A novel DNA methylation score accurately predicts death from prostate cancer in men with low to intermediate clinical risk factors.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

7 January 2021

Gene expression correlates of clinical prostate cancer behavior

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

7 January 2021

Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

7 January 2021

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2017.168

7 January 2021

10.1038/MODPATHOL.2017.168

Identifiers

DOI

1 reference

11 January 2018

1 reference

11 January 2018